Jonathan H. Dinsmore
Keine laufenden Positionen mehr
Profil
Jonathan H.
Dinsmore is Senior Vice President-Regulatory and Clinical of Advanced Cell Technology, Inc. Previously, he was President, Chief Scientific Officer and a Director of Mytogen, Inc. Dr. Dinsmore worked for Diacrin and GenVec.
He received a BS degree in Biology from Boston College in 1983 and a PhD degree in Biology from Dartmouth College in 1988.
Ehemalige bekannte Positionen von Jonathan H. Dinsmore
| Unternehmen | Position | Ende |
|---|---|---|
| OCATA THERAPEUTICS INC | General Counsel | - |
Mytogen, Inc.
 Mytogen, Inc. BiotechnologyHealth Technology Mytogen, Inc. provides healthcare services. It focuses on using myoblasts, stem cells that form muscle, to treat patients with cardiac indications such as congestive heart failure, a progressive deterioration of the heart muscle. The company was founded in 1990 and is headquartered in Los Angeles, CA. | Präsident | - |
Ausbildung von Jonathan H. Dinsmore
| Boston College | Undergraduate Degree |
| Dartmouth College | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Mytogen, Inc.
Mytogen, Inc. BiotechnologyHealth Technology Mytogen, Inc. provides healthcare services. It focuses on using myoblasts, stem cells that form muscle, to treat patients with cardiac indications such as congestive heart failure, a progressive deterioration of the heart muscle. The company was founded in 1990 and is headquartered in Los Angeles, CA. | Health Technology |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
